Literature DB >> 35809868

Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.

Timothy Qi1, Kyle McGrath2, Raghuveer Ranganathan3, Gianpietro Dotti4, Yanguang Cao5.   

Abstract

To the extent that pharmacokinetics influence the effectiveness of nonliving therapeutics, so too do cellular kinetics influence the efficacy of Chimeric Antigen Receptor (CAR) -T cell therapy. Like conventional therapeutics, CAR-T cell therapies undergo a distribution phase upon administration. Unlike other therapeutics, however, this distribution phase is followed by subsequent phases of expansion, contraction, and persistence. The magnitude and duration of these phases unequivocally influence clinical outcomes. Furthermore, the "pharmacodynamics" of CAR-T cells is truly dynamic, as cells can rapidly become exhausted and lose their therapeutic efficacy. Mathematical models are among the translational tools commonly applied to assess, characterize, and predict the complex cellular kinetics and dynamics of CAR-T cells. Here, we provide a focused review of the cellular kinetics of CAR-T cells, the mechanisms underpinning their complexity, and the mathematical modeling approaches used to interrogate them.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CAR-T cells; Cancer immunology; Immunotherapy; Lymphocyte trafficking; Mathematical modeling; Translational science

Mesh:

Substances:

Year:  2022        PMID: 35809868      PMCID: PMC9520251          DOI: 10.1016/j.addr.2022.114421

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   17.873


  125 in total

1.  Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.

Authors:  Elise A Chong; Marco Ruella; Stephen J Schuster
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

2.  GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Authors:  Tessa Gargett; Wenbo Yu; Gianpietro Dotti; Eric S Yvon; Susan N Christo; John D Hayball; Ian D Lewis; Malcolm K Brenner; Michael P Brown
Journal:  Mol Ther       Date:  2016-03-29       Impact factor: 11.454

3.  Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy.

Authors:  H Zhu; R J Melder; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

4.  Spatial map of human T cell compartmentalization and maintenance over decades of life.

Authors:  Joseph J C Thome; Naomi Yudanin; Yoshiaki Ohmura; Masaru Kubota; Boris Grinshpun; Taheri Sathaliyawala; Tomoaki Kato; Harvey Lerner; Yufeng Shen; Donna L Farber
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

5.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Authors:  Jesus G Berdeja; Deepu Madduri; Saad Z Usmani; Andrzej Jakubowiak; Mounzer Agha; Adam D Cohen; A Keith Stewart; Parameswaran Hari; Myo Htut; Alexander Lesokhin; Abhinav Deol; Nikhil C Munshi; Elizabeth O'Donnell; David Avigan; Indrajeet Singh; Enrique Zudaire; Tzu-Min Yeh; Alicia J Allred; Yunsi Olyslager; Arnob Banerjee; Carolyn C Jackson; Jenna D Goldberg; Jordan M Schecter; William Deraedt; Sen Hong Zhuang; Jeffrey Infante; Dong Geng; Xiaoling Wu; Marlene J Carrasco-Alfonso; Muhammad Akram; Farah Hossain; Syed Rizvi; Frank Fan; Yi Lin; Thomas Martin; Sundar Jagannath
Journal:  Lancet       Date:  2021-06-24       Impact factor: 79.321

6.  Induction of CD4 T cell memory by local cellular collectivity.

Authors:  Michal Polonsky; Jacob Rimer; Amos Kern-Perets; Irina Zaretsky; Stav Miller; Chamutal Bornstein; Eyal David; Naama Meira Kopelman; Gil Stelzer; Ziv Porat; Benjamin Chain; Nir Friedman
Journal:  Science       Date:  2018-06-15       Impact factor: 47.728

Review 7.  Systemic effects of local radiotherapy.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Lancet Oncol       Date:  2009-07       Impact factor: 41.316

8.  Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU.

Authors:  Gianpietro Dotti; Mei Tian; Barbara Savoldo; Amer Najjar; Laurence J N Cooper; James Jackson; Amanda Smith; Osama Mawlawi; Rajesh Uthamanthil; Agatha Borne; David Brammer; Vincenzo Paolillo; Mian Alauddin; Carlos Gonzalez; David Steiner; William K Decker; Frank Marini; Steven Kornblau; Catherine M Bollard; Elizabeth J Shpall; Juri G Gelovani
Journal:  Mol Imaging       Date:  2009 Jul-Aug       Impact factor: 4.488

9.  Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

Authors:  Xin-An Lu; Yuqin Song; Jun Zhu; Zhitao Ying; Ting He; Xiaopei Wang; Wen Zheng; Ningjing Lin; Meifeng Tu; Yan Xie; Lingyan Ping; Chen Zhang; Weiping Liu; Lijuan Deng; Meng Wu; Feier Feng; Xin Leng; Tingting Du; Feifei Qi; Xuelian Hu; Yanping Ding
Journal:  BMC Cancer       Date:  2021-02-25       Impact factor: 4.430

10.  Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.

Authors:  Ken Ogasawara; Michael Dodds; Timothy Mack; James Lymp; Justine Dell'Aringa; Jeff Smith
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.